Nalaganje...
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
Idarucizumab is the first targeted antidote of dabigatran, a direct oral anticoagulant used for prevention and treatment of venous thromboembolism and prevention of stroke in atrial fibrillation. Idarucizumab is a humanized fragment of a monoclonal antibody, which binds dabigatran reversibly with hi...
Shranjeno v:
| izdano v: | Drug Des Devel Ther |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4876800/ https://ncbi.nlm.nih.gov/pubmed/27274201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S94167 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|